

Haematologica  
HAEMATOL/2018/200014  
Version 3

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase 2 study SAKK 33/14

Beatrice Drexler, Jakob R. Passweg, Alexandar Tzankov, Martin Bigler, Alexandre P.A. Theoharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz, Geneviève Favre, Pontus Lundberg, Ronny Nienhold, Andrea Fuhrer, Christine Biaggi, Markus G. Manz, Mario Bargetzi, Simon Mendez-Ferrer, and Radek C. Skoda  
Collaborative Groups: Swiss Group for Clinical Cancer Research (SAKK)

Disclosures: The authors declare no competing financial interests.

Contributions: B.D. performed research, analyzed data and wrote the manuscript, J.P. designed research, analyzed data and wrote the manuscript, A. T. performed research and analyzed histopathology data, M. Bigler performed statistical analysis, A.P.A.T., N.C., P.K., G.S., A.R., R.B., and G.F. performed research, P.L., and R.N. performed research, A.F. and C.B. collected data, M.G.M. and M. Bargetzi performed research, S.M.F. designed research and analyzed data, R.C.S. designed research, analyzed data and wrote the manuscript.